Latest CLIC Content

Latest News from Around the CTSA Program Consortium

License: creativecommons.org /licenses/by/4.0/.
First Successful Use of a Patient-Derived Xenograft (PDX) Model to Guide Cancer Treatment

Clinical and Translational Science Collaborative of Cleveland

Mohamed Abazeed, MD, PhD became a CTSC KL2 Scholar in 2015. His research program focuses on identifying the genetic abnormalities that give rise to therapeutic resistance in cancer and using this information to develop personalized therapeutic strategies in a new strategy of biologically-guided treatments. He uses his experiences in patient care to develop a clinically relevant research program to study cancers and to translate laboratory discoveries into potential improvements in clinical care.

Patient-derived xenograft (PDX) models (immunodeficient mice engrafted with patients’ cancerous cells or tissues) have significantly enhanced cancer research in recent years. However, using PDX models to meet the urgent need for human cancer models to reliably predict clinical activity has proved challenging. Most cancer patients can’t wait months for the cells to become engrafted and grow and be used to test multiple drugs. "The average cancer grows too slowly to use PDX models to guide clinical decision-making. The patient will have received treatment long before the engraftment is ready for testing. By selecting cancers that grow aggressively, we can potentially develop PDX models in a timeframe that is clinically actionable. Using the PDX model, we were able to prospectively predict the patient’s response to first-line therapy and identify the most optimal second-line therapy,” says Dr. Abazeed.

August 15, 2018

Innovation & Awards Program OCTRI
Three researchers receive 2018 Biomedical Innovation Program Drug Discovery awards

Oregon Clinical & Translational Research Institute

Three drug discovery projects have been named recipients of the 2018 Biomedical Innovation Program awards. The awards program is a collaboration of the Oregon Clinical and Translational Research Institute and Technology Transfer and Business Development.

The awards provide funds, project management, and mentorship to facilitate the development of innovative technologies at OHSU and accelerate their translation to the marketplace. This track of funding supports drug discovery platforms and early stage therapeutic technology projects.

August 15, 2018

Robert Schuff, OCTRI Informatics Program Director, OHSU
REDCap module brings new charting functionality to clinical research projects

Oregon Clinical & Translational Research Institute

The Oregon Clinical and Translational Research Institute’s informatics team has launched a new REDCap module for data visualization at OHSU. Over 2,400 OHSU researchers use REDCap to manage research data for their collective 1,600 projects.

While REDCap includes a wide variety of research data collection, management, reporting and security features that robustly support clinical research, Vizr brings new charting functionality to support recruitment and retention tracking, one of the most critical factors to successful clinical research projects. Vizr provides a flexible and intuitive way for investigators to monitor recruitment and retention performance against targets in real time. Vizr supports single and multi-site clinical research studies with ease as the figure shows.

August 15, 2018

Pittsburgh Works to Close Digital Divide with Health-Focused Apps

University of Pittsburgh CTSI

Technology is revolutionizing the healthcare industry, from the way we treat and dispense medicine to the greater control consumers can take over their health. The National Urban wants to make sure the Black community is an integral part of this new landscape.

August 13, 2018

Twitter logoFollow CLIC
Twitter logoFollow NCATS